Authors | QoL results | Time point | Value | Reference interval | Percent impairment (overall QoL on opposite scaling) | |
---|---|---|---|---|---|---|
Goossens-Laan et al. [12] | WHOQOL-bref: overall QoL | before diagnosis | 3.8 | 2-10 | 22.5 | |
SF-12 overall (sum of general domains /6) | 0-100 | 61.4 | ||||
SF-12: bodily pain | 76.2 | 0-100 | 23.8 | |||
SF-12: fatigue | 60.7 | 0-100 | 39.3 | |||
IIEF: erectile dysfunction | 93.1 | 0-100 | 93.1 | |||
Lagrange et al. [27] | QLQ-C30: Overall QoL | before treatment | 68 | 0-100 | 68 | |
after treatment | 6 mths | 60 | 0-100 | 60 | ||
12 mths | 81 | 0-100 | 81 | |||
24 mths | 68 | 0-100 | 68 | |||
36 mths | 71 | 0-100 | 71 | |||
Non-validated: urinary | before treatment | 56.5 | 0-100 | 56.5 | ||
after treatment | 6 mths | 48.2 | 0-100 | 48.2 | ||
12 mths | 30 | 0-100 | 30 | |||
24 mths | 37.5 | 0-100 | 37.5 | |||
36 mths | 64.3 | 0-100 | 64.3 | |||
Fung et al. [11] | Scores not in comparable scale | |||||
Roychowdhury et al. [14] | QLQ-C30: Overall QoL | Baseline before CT | 58.3 | 0-100 | 58.3 | |
Pain | Baseline before CT | 33.3 | 0-100 | 33.3 | ||
Fatigue | Baseline before CT | 33.3 | 0-100 | 33.3 | ||
Albers et al. [19] | Spitzer: overall QoL | before CT (after TUR) | 7.9 | 0-10 | 79 | |
after CT | at end of treatment | 7.4 | 0-10 | 74 | ||
Spitzer: pain | before CT (after TUR) | 4.8 | 0-7 | 52 | ||
after CT | at end of treatment | 5.3 | 0-7 | 47 | ||
Herman et al. [18] | FACT-G: overall | before | 94.5 | 0-108 | 87.5 | |
during | 3 weeks after initiating treatment | 95.2 | 0-108 | 88.1 | ||
after | 2 weeks after treatment(8 wks after treatment initiation) | 96.2 | 0-108 | 89 | ||
FACT-BL | before | 37.1 | 0-156 | 76.2 | ||
during | 3 weeks after initiating treatment | 36 | 0-156 | 76.9 | ||
after | 2 weeks after treatment(8 wks after treatment initiation) | 34.3 | 0-156 | 78 | ||
subcategory: bowel | before, during, after | 71 | ||||
subcategory: erectile function | before, during, after | 58 | ||||
Butt et al. [37] | Overview paper, not specified for BC patients | |||||
Joly et al. [16] | FACT-G: overall | during | 1 week after start of treatment | 77 | 0-108 | 71.3 |
2 weeks | 79 | 0-108 | 73.1 | |||
3 weeks | 82 | 0-108 | 75.9 | |||
4 weeks | 78 | 0-108 | 72.2 | |||
5 weeks | 72 | 0-108 | 66.7 | |||
6 weeks | 71 | 0-108 | 65.7 | |||
FACT-BL | during | 1 week after start of treatment | 107 | 0-156 | 31.4 | |
2 weeks | 110 | 0-156 | 29.5 | |||
3 weeks | 117 | 0-156 | 25 | |||
4 weeks | 118 | 0-156 | 24.4 | |||
5 weeks | 104 | 0-156 | 33.3 | |||
6 weeks | 104 | 0-156 | 33.3 | |||
De Santis et al. [17] | No QoL scores listed | |||||
Huddart et el. [22] | Scores not in comparable scale | |||||
Henningsohn et al. [23] | Non-validated: urinary | after treatment | 1-19 yrs after RT treatment | 41 | 0-100 | 41 |
Non-validated: bowel | after treatment | 1-19 yrs after RT treatment | 22.75 | 0-100 | 22.75 | |
Non-validated: sexual | after treatment | 1-19 yrs after RT treatment | 62 | 0-100 | 62 | |
Zietman et al. [24] | Non-validated: urinary | after treatment | 1-15 yrs after treatment | 13.3 | 0-100 | 13.3 |
Non-validated: bowel | after treatment | 1-15 yrs after treatment | 14.3 | 0-100 | 14.3 | |
Prostate instrument/Index for women: sexual | after treatment | 1-15 yrs after treatment | 53.7 | 0-100 | 53.7 | |
SF-36: overall | after treatment | 1-15 yrs after treatment | 74 | 0-100 | 74 | |
Matsuda et al. [35] | FACT-G: overall | after | 5-10 yrs | 81 | 0-108 | 75 |
FACT-BL | after | 5-10 yrs | 116.8 | 0-156 | 25.1 | |
Fokdal et al. [26] | LENTSOMA: urinary | after | 3-10 yrs after treatment | 42.3 | 0-100 | 42.3 |
bowel | after | 3-10 yrs after treatment | 32 | 0-100 | 32 | |
sexual | after | 3-10 yrs after treatment | 89 | 0-100 | 89 | |
Allareddy et al. [25] | FACT-G: overall | after | 6-16 yrs | 89 | 0-104 | 85.6 |
FACT-BL | after | 6-16 yrs | 125 | 0-156 | 17.8 | |
sexual function | after | 6-16 yrs | 32 | 0-100 | 32 | |
Hashine et al. [21] | SF-36: overall (sum of all scales /8) | after | 1-14 yrs after RT treatment | 73 | 0-100 | 73 |
subcategory: body pain | after | 1-14 yrs after RT treatment | 79.2 | 0-100 | 79.2 | |
EPIC: bowel | after | 1-14 yrs after RT treatment | 90 | 0-100 | 90 | |
EPIC: urinary | after | 1-14 yrs after RT treatment | 92 | 0-100 | 92 | |
EPIC: sexual | after | 1-14 yrs after RT treatment | 90 | 0-100 | 90 | |
Singer et el. [34] | QLQ-C30: overall (sum of general scales /6) | after | 0-37 yrs after | 51.7 | 0-100 | 51.7 |
Subcategory: pain | after | 0-37 yrs after | 43.8 | 0-100 | 43.8 | |
Subcategory: fatigue | after | 0-37 yrs after | 63.7 | 0-100 | 63.7 | |
Kent et al. [38] | Overview paper, not specified for BC patients | |||||
Mak et. al. [20] | QLQ-C30: Overall (sum of general scales /6) | after | 2-16 yrs after treatment | 88.2 | 0-100 | 88.2 |
Subcategory: fatigue | 15 | 0-100 | 15 | |||
Subcategory: pain | 10 | 0-100 | 10 | |||
EQ-5D(3L): overall | 91 | 0-100 | 91 | |||
EQ-5D:VAS: overall | 81 | 0-100 | 81 | |||
QLQ-BLM30: urinary | 22 | 0-100 | 22 | |||
QLQ-BLM30: sexual | 52 | 0-100 | 52 | |||
EPIC: bowel | 87 | 0-100 | 87 | |||
Mason et al. [36] | EQ5D | 1-5 years post diagnosis, no comparable scores. | ||||
Perlis et al. [13] | BUSS: overall QoL | After | >1 year after | 72.5 | 0-100 | 72.5 |